National Institute of Allergy and Infectious Diseases (NIAID)

139 Protocols (106 Active Accrual of new subjects, 33 Follow-up of previously enrolled subjects)

 08-I-0209:

A Multicenter, Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, and Efficacy of AVONEX in Subjects with Moderate to Severe Ulcerative Colitis

 08-I-0201:

Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection

 08-I-0184:

Studies in the Pathogenesis of Idiopathic Anaphylaxis

 08-I-0174:

A Pilot Study of Therapy with Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects with Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy

 08-I-0171:

A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection

 08-I-0093:

A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC

 08-I-0065:

VRC 206: A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults

 08-I-0063:

A Phase III, Multicenter Placebo-Controlled, Randomized, Double-Blind Study to Evaluate Safety/Efficacy of PROCHYMALTM IV Infusion for Induction of Remission in Subjects Experiencing Tx of Refractory Moderate to Severe Crohn's Disease

 08-I-0053:

Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)

 08-I-0034:

Validation of (1)H-Magnetic Resonance Spectroscopy for Quantification of Hepatic Triglyceride Content

 07-I-0229:

Influenza in the Immunocompromised Host

 07-I-0218:

A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations

 07-I-0205:

An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis

 07-I-0183:

The Collection of Research Samples and/or Data for Repository from Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program

 07-I-0171:

Treatment for Growth Failure in Patients with X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment with Insulin-like Growth Factor-1 (IGF-1)

 07-I-0167:

VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules with an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults

 07-I-0142:

Research Respiratory Tract Procedures in Healthy Adult Volunteers and Adult Patients to Obtain Specimens for In Vitro Analyses of Infection Pathogenesis and Susceptibility

 07-I-0105:

Pioglitazone for Hepatic Steatosis in HIV

 07-I-0094:

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

 07-I-0075:

Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies: Busulfan-based Conditioning with Campath- 1H or h-ATG, Radiation, and Sirolimus

 07-I-0033:

Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

 07-I-0017:

Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease

 07-I-0001:

An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks with Ribavirin among HIV/HCV Coinfected Individuals

 06-I-0237:

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults

 06-I-0235:

A Phase II Vaccine Dose Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin

 06-I-0217:

Genetic Disorders of Mucociliary Clearance

 06-I-0207:

Investigation of Southern Tick-Associated Rash Illness (STARI)

 06-I-0197:

A Randomized Placebo Controlled Trial of Atorvastatin in HIV Positive Patients Not on Antiretroviral Medications with the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers

 06-I-0160:

Infliximab Treatment for Crohn's-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences

 06-I-0106:

High Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial

 06-I-0086:

A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients with CD4 Count Less Than or Equal to 100 Cells/micro L Who Are Initiating Antiretroviral Therapy

 06-I-0077:

Voriconazole Plasma Concentration and Toxicity

 06-I-0074:

Collection of Blood from Persons with Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research

 06-I-0049:

Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

 06-I-0032:

Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome

 06-I-0030:

Correlation of the Precursor Frequency of CD4 + Effector Memory T Cells with Induration Measured in the Tuberculin Skin Test (TST)

 06-I-0015:

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

 06-I-0005:

Evaluation of Risk Factors for Development of Epstein-Barr Virus Lymphoproliferative Disease

 05-I-0219:

Microarray Analysis of Erythema Migrans Lesions

 05-I-0213:

Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

 05-I-0156:

A Study of Adjuvant Cytokine Therapy in Pulmonary Mycobacterium Avium Complex Infection

 05-I-0123:

A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Participants w/HIV-1 Infection and CD4+ Cell Counts Greater Than or Equal to 300/mm(3)

 05-I-0084:

Clinical and Immunological Evaluation of Children with Allergic Disease

 04-I-0286:

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

 04-I-0231:

Procurement of Clinical Specimens for Immunologic or Genetic Studies in Inflammatory Bowel Diseases

 04-I-0086:

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research on HCV-Infected Patients

 04-I-0030:

Clinical Evaluation and Management of Persons with Severe Acute Respiratory Syndrome (SARS)

 03-I-0285:

VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases

 03-I-0263:

Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

 03-I-0151:

Evaluation and Treatment of Persons with Serious Complications Associated with Vaccinia Vaccination

 03-I-0090:

Immune Responses to Vaccinia Virus Vaccination

 03-I-0079:

Screening HIV-Infected Subjects for Vaccine Research Studies

 03-I-0041:

Determining the Pathogenesis of Systemic Pediatric-Onset Mastocytosis

 03-I-0025:

Treatment of Chronic Graft Versus Host Disease with Extracorporeal Photopheresis

 02-I-0308:

Study of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Evaluation of the Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Associated Lymphoma

 02-I-0286:

A Pilot Study of the Safety and Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients with the Myeloproliferative Variant Hypereosinophilic Syndrome (HES) or Non-Myeloproliferative HES Refractory to Standard Therapy

 02-I-0277:

Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells

 02-I-0232:

HIV Expression in Patients with Viral Loads Suppressed on HAART

 02-I-0202:

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-Infected Patients

 02-I-0147:

Genetic Studies of Chronic Active Epstein-Barr Virus Infection

 02-I-0127:

Screening Subjects for HIV Vaccine Research Studies

 02-I-0110:

Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients

 02-I-0096:

Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis

 02-I-0086:

Leukapheresis Procedures to Study HIV-Specific Immunity

 02-I-0057:

Ex Vivo Retroviral Gene Transfer For Treatment of X-Linked Severe Combined Immunodeficiency (XSCID)

 02-I-0055:

Evaluation, Treatment and Follow up of Patients with Lyme Disease

 01-I-0238:

Diagnosis and Treatment of Leishmanial Infections

 01-I-0226:

Evaluation of Immune Response to Vaccines in Primary Immune Disorders

 01-I-0225:

An Omnibus Proleukin (IL-2) Trial in HIV-Infected Patients Including Interrupted Versus Continuous Antiretrovirals (OPTICA): A Substudy of Interrupted Versus Continuous Antiretrovirals Involving Randomization From the Umbrella Study (ICARUS)

 01-I-0202:

Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections

 01-I-0194:

A Non-Randomized, Open label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients with Hepatitis C Infection Coinfected with HIV-1 Treated with Peginterferon Alpha-2b and Ribavirin

 01-I-0161:

Identification of Novel Viruses

 01-I-0153:

The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency

 01-I-0004:

An Assessment of the Relationship Between Antiretroviral Drug Genotype/Phenotype (IC50) and Antiretroviral Activity in HIV-Infected, Drug-Experienced Patients with Suboptimal Suppression of Plasma Viral Load

 00-I-0159:

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection (Job) Syndrome

 00-I-0099:

Langherhans' Cell Function and Inflammatory Responses in Skin of Normal Volunteers and Patients with Helminth Infections Using the Suction Blister Technique

 99-I-0084:

To Develop a New Technique to Predict the Occurrence of Pneumocystis Pneumonia, Track its Epidemiology, Diagnose Acute Disease, and Predict and Monitor the Response to Various Therapeutic Agents

 98-I-0070:

Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects

 98-I-0027:

The Characterization of CD34+ Derived Mast Cell Precursors Mobilized by Administration of Granulocyte Colony Stimulating Factor

 97-I-0191:

Studies of Lymphocyte Kinetics Using Stable Isotopes

 97-I-0096:

Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection

 96-I-0129:

Evaluation and Long Term Follow-up of Patients with Allergic and Inflammatory Disorders

 96-I-0085:

Genetic Studies of the X-Linked Lymphoproliferative Disease

 96-I-0052:

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients with Suspected Chronic Lyme Infection and Selected Control Populations

 95-I-0072:

Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients with Known or Suspected HIV Infection

 95-I-0066:

Genetic Analysis of Immune Disorders

 95-I-0027:

Virologic and Immunologic Evaluation of Lymph Node, Tonsillar, and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid

 94-I-0079:

Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in Humans

 94-I-0073:

Recruitment of Peripheral Blood Hematopoietic Progenitors by Granulocyte Colony Stimulating Factor (G-CSF)

 93-I-0119:

Detection and Characterization of Host Defense Defects

 93-I-0106:

Cryptococcosis in Previously Normal Adults

 93-I-0086:

Evaluation and Long Term Follow Up of Patients with Acute or Chronic Inflammatory Disorders

 93-I-0063:

Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells and Defective Lymphocyte Apoptosis

 93-I-0057:

Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies

 92-I-0125:

A Study of Viral Burden in Peripheral Blood versus Lymphoid and Bone Marrow Tissue in Human Immunodeficiency Virus Infected Individuals

 91-I-0140:

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-Infected and HIV-Uninfected Volunteers

 90-I-0120:

Comparison of Inflammatory Responses in Normal Volunteers and Patients with Abnormal Phagocyte Function Using the Suction Blister Technique

 89-I-0174:

Study of Patients with Known or Suspected Infection with Strongyloides Stercoralis

 89-I-0158:

Studies of Immune Regulation in Patients with Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes

 88-I-0083:

Host Response to Infection and Treatment in the Filarial Diseases of Humans

Next 39 Protocols

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 09/17/2008